| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 13, 2020Full-Body MRI-Conditional InterStim II and InterStim Micro Systems Offer Lifestyle-Friendly Choices in Sacral Neuromodulation Therapy to Europeans Suffering from Incontinence
DUBLIN, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has received CE Mark for its InterStim™ Micro neurostimulator and InterStim™ SureScan™ MRI leads —...
-
Jan 9, 2020This Next-Generation DBS Technology Allows Physicians to Review Patient-Specific Brain Signals, Enabling More Personalized, Data-Driven Neurostimulation Treatment for Patients
DUBLIN, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the CE (Conformité Européenne) Mark for Percept™ PC neurostimulator; it is the only Deep Brain Stimulation...
-
Jan 8, 2020Randomized Control Trial Results to be Presented at NANS Jan. 23-26 in Las Vegas; New, Proprietary Differential Target Multiplexed (DTM) Therapy Available on Medtronic Intellis Spinal Cord Stimulation Platform
DUBLIN, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) announced it has acquired Stimgenics, LLC, a privately-held company based in Bloomington, Illinois, that has pioneered a novel...
-
Jan 6, 2020
DUBLIN, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 38th Annual J.P. Morgan Healthcare...
-
Dec 18, 2019Robotic Trajectory Guidance Platform Integrates Multiple Enabling Technologies to Support Complex Cranial Procedures
DUBLIN, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) announced that the U.S. Food and Drug Administration (FDA) recently cleared the Stealth Autoguide™ system, the first cranial...